Correspondence  by unknown
tient age, underlying cardiovascular disease or use of antiarrhythmic
drug therapy, but not so after adjustment for left ventricular ejection
fraction, left atrial diameter or duration of atrial fibrillation. We feel
that our results justify the conclusion that “patients who undergo
electrical cardioversion display a greater degree and longer duration of
mechanical atrial dysfunction than those who convert pharmacologi-
cally or spontaneously” (1).
We agree with Falk et al. that some of the patients who underwent
electrical cardioversion may have had attempts at pharmacologic
cardioversion in the past. By the same token, some of the patients who
had pharmacologic cardioversion in our study had also undergone
previous attempts at cardioversion. Previous history of cardioversion
attempts was not specifically monitored in our study; hence, we are
unable to comment on the actual number of study patients who had
had previous attempts at cardioversion. To say that “the study is
predominantly a comparison of patients who responded to pharmaco-
logic agents compared with those in whom pharmacologic cardiover-
sion failed” is therefore erroneous.
To the best of our knowledge, there is only one previous study that
showed that duration of atrial fibrillation ,14 days (vs. .6 weeks) is
associated with faster recovery of atrial function (2). In that particular
study, no multivariate analysis was performed to account for differ-
ences between groups of patients who had atrial fibrillation ,14 days
versus .6 weeks. For this reason, we are not convinced that atrial
fibrillation duration ,14 days should be a standard reference division
point for all future studies with regard to atrial fibrillation. Until more
definitive information is available on the impact of duration of atrial
fibrillation on atrial function recovery, any dichotomization of this
variable will have to be “arbitrary.” The division of atrial fibrillation
duration in our study is identical to the inclusion criterion used by Falk
et al. in their study addressing postcardioversion atrial function (3).
Due to uncertainty about the exact duration of atrial fibrillation in
many cases, it is not feasible to use duration of atrial fibrillation as a
continuous variable.
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Before Predicting Survival in Children With
Pulmonary Hypertension and Congenital
Heart Disease . . .
In the recent article by Clabby et al. (1), the authors provide very
interesting data on the predictive value of hemodynamic data with
respect to survival in pediatric patients with primary and secondary
pulmonary hypertension. In primary pulmonary hypertension, such
data have been reported earlier (2,3). In patients with plexogenic
arteriopathy and congenital heart disease, these data are scarce (4).
The design of this study has led to the pitfalls of highly selected
patient population and small sample size in relation to the used
analysis techniques, and consequently the results have to be inter-
preted with great caution. The most serious problem with the study
design is the composition of group 2. This group includes patients with
repaired and unrepaired heart defects, which leads to two comments
on the interpretation of the data:
1. In patients with persistent pulmonary hypertension after ade-
quate surgical repair of a heart defect, hemodynamic variables are
comparable to those in patients with primary pulmonary hypertension.
In contrast, in patients with unrepaired heart defects or residual
shunts, hemodynamic variables cannot be interpreted in the same way.
The authors suggest that the variable “mean right atrial pressure
(mRAP) 3 pulmonary vascular resistance (PVR)” represents the
pressure load on the right ventricle and indicates how well the right
ventricle handles that pressure. However, in children with large
intracardiac communications, with or without transposition of the
great arteries, increased PVR is not simply a pressure load for the right
ventricle and ventricular dysfunction does not necessarily lead to
increased mRAP.
2. More important, the authors conclude that survival in children
with pulmonary hypertension in the presence of congenital heart
defects, as predicted by the suggested hemodynamic variables, can be
used to determine the optimal timing of lung transplantation. How-
ever, before predicting survival or scheduling lung transplantation, the
question to be addressed is whether the pulmonary arteriopathy has
progressed to the irreversible stage. Pulmonary plexogenic arteriopa-
thy in children with left to right shunts is a reversible disease until a
so-called “point of no return” is reached, at which the process has
become irreversible, and progression will occur even if the heart defect
is corrected (5). In the reversible stage, the treatment of choice will
obviously be surgical correction of the heart defect. It can be specu-
lated that the pulmonary vascular disease might have been still
reversible in some of the study patients: In 80% of group 2 patients, the
heart defect was unrepaired or palliated, or residual defects were
present, whereas right to left shunting was present in only 29%.
Hemodynamic or histologic evaluation is currently used to assess the
progression of pulmonary vascular disease. However, criteria to pre-
dict in which patients pulmonary vascular disease will progress despite
surgical correction have a broad gray zone (5,6). Therefore, before
including these children in a study to predict survival in patients with
irreversible pulmonary vascular disease, we should be able to deter-
mine the reversibility of this disease process more accurately.
In other words, one does not want to predict the optimal timing for
lung transplantation in children who may be cured by surgical correc-
tion of their heart disease.
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Reply
We appreciate the interest of Berger and colleagues in our report. We
agree with their comments regarding the differences that exist between
patients with and without intracardiac defects. These differences
almost certainly affect the rate at which symptoms and unstable
physiology develop in patients with elevated pulmonary vascular
resistance. In interpreting our results, the reader must keep in mind
that survival in our study (1) was measured from the date of cardiac
catheterization, not from the date of birth or the date of diagnosis. The
multivariable analysis takes into account the presence or absence of
structural heart disease as a potential predictor of survival. It also takes
into account the pulmonary/systolic flow ratio (Qp/Qs)—a reasonable
indicator of the presence or absence of a residual shunt lesion, when
the pulmonary vein and systemic arterial oxygen saturations are
known, as required by our entry criteria. The result of the analysis
indicates that the predictive power of the hemodynamic variables is
significant at 1 or 2 years of follow-up, with or without structural heart
disease and with or without a residual shunt.
We also agree that the child with pulmonary vascular disease must
undergo thorough evaluation, including drug testing, to elicit revers-
ibility of pulmonary vascular disease; that a surgically correctable cause
of pulmonary hypertension must be sought and excluded in all cases;
and that lung transplantation should only be considered when all other
therapeutic options have been explored (2,3). The evaluation of
children for lung transplantation is extensive, and the result of that
evaluation is never determined by any one value. However, it is also
clear that a substantial proportion of children with pulmonary hyper-
tension are referred for transplantation when they have very advanced
disease and cannot be expected to survive until organs become
available (4). Thus, it behooves us to try to determine how we might
best predict survival in these patients. We do not argue that every child
included in our study was or will be a candidate for lung transplanta-
tion; rather, we argue that every child in our study had, by definition,
pulmonary hypertension and that their survival at 1 and 2 years of
follow-up was significantly related to their hemodynamic status. We
suspect that when medical management results in a favorable change
in hemodynamic status, it also improves predicted survival, but that
question could not be addressed by our study design.
Finally, we agree (as stated in our report) that our study has
limitations. Any retrospective, multicenter study must be viewed as less
than definitive. We limited our patients to those for whom the data had
been collected meticulously enough to be deemed reliable. The sample
size is small. Nevertheless, in the context of the existing body of
knowledge, we stand by our conclusions. We hope that our work will
stimulate increased interest and work in this area—particularly, the
evaluation and management of children with nonprimary forms of
pulmonary hypertension—and thus to more data and better decision
making.
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